research communications\(\def\hfill{\hskip 5em}\def\hfil{\hskip 3em}\def\eqno#1{\hfil {#1}}\)

Journal logoSTRUCTURAL BIOLOGY
COMMUNICATIONS
ISSN: 2053-230X

Diverse DTPA-chelated lanthanides with relevance for nuclear medicine bound to an engineered lipocalin reveal conserved ligand geometry

crossmark logo

aSchool of Life Sciences, Technical University of Munich, 85354 Freising, Germany
*Correspondence e-mail: [email protected]

Edited by R. L. Stanfield, The Scripps Research Institute, USA (Received 9 June 2026; accepted 24 July 2026; online 17 August 2026)

The Anticalin CL31d, an engineered lipocalin protein previously designed to specifically bind rare-earth and related metal ions as chelate complexes with p-NH2-Bn-CHX-A″-DTPA (DTPA-NH2), was subjected to structural and binding studies with a series of 11 different MIII·DTPA-NH2 complexes. These complexes include various lanthanide and main-group metal(III) ions whose radioisotopes are useful in nuclear medicine, with ionic radii ranging from 0.62 to 1.03 Å. Binding activities of the Anticalin for the MIII·DTPA-NH2 complexes were quantified by fluorescence titration (probing the intrinsic Tyr/Trp emission), revealing Kd values of 0.8–2.4 nM for most of the lanthanide ions investigated (rion = 0.75–0.96 Å), but showing markedly reduced affinities towards the small and large main-group metal ions Ga3+ (Kd = 15.3 nM) and Bi3+ (Kd = 47.8 nM), respectively. The crystal structures of six representative MIII·DTPA-NH2 complexes bound to the Anticalin were solved at high resolution (1.5–1.8 Å) using synchrotron X-ray diffraction. Superposition onto the previously described Anticalin CL31 with bound Y3+·DTPA-SCN indicated an essentially invariant conformation both for the binding protein and its metal-chelate ligands, including conserved hydrogen bonds, and a surprisingly uniform ninefold metal coordination via five carboxylate groups, three N atoms and one water molecule. However, there were two exceptions: the small Sc3+ ion appeared to be coordinated only eightfold with the DTPA-NH2 chelator but lacking the water ligand, whereas no metal electron density was observed for the Ga3+ ion, in line with its known noncanonical DTPA complex geometry. Interestingly, in this case a water molecule was detected at the expected position of the central metal ion within the protein-bound DTPA-NH2 chelator. Our investigation of the influence of chelate geometry on complex stability establishes the Anticalin CL31d as a small and robust universal binding protein for medically relevant MIII·DTPA complexes with surprisingly broad tolerance towards varying ionic radii, thus enabling flexible radionuclide-targeting strategies in nuclear medicine.

1. Introduction

Antibodies offer huge potential for both in vivo diagnostics and tumor therapy, nowadays referred to as theranostics (Burkett et al., 2023View full citation), due to their high specificity and affinity towards disease-relevant molecular targets (Goldenberg & Sharkey, 2006View full citation; Milenic et al., 2004View full citation). However, their large size limits tissue penetration and leads to prolonged circulation, which can hamper tumor-imaging applications via positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (Boswell & Brechbiel, 2007View full citation; Löfblom et al., 2011View full citation). Although antibody fragments such as Fab or scFv, as well as single-domain immunoglobulins (Igs) from camels or sharks, alleviate some of these limitations (Holliger & Hudson, 2005View full citation), there remains considerable interest in alternative non-Ig protein scaffolds that offer comparable high-affinity and specific target recognition. Over the past two decades, more than 50 such non-Ig binding proteins with engineered ligand specificities have been described (Gebauer & Skerra, 2019View full citation), with a subset already investigated for PET and SPECT imaging applications. For conventional tumor imaging, both antibody-derived and non-Ig binding proteins are chemically conjugated to a radionuclide, potentially mediated by a metal chelator, and employed to target a disease-related antigen.

Alternatively, such binding proteins may serve to fix the radionuclide by way of biomolecular recognition and non­covalent complex formation, for example as part of a bispecific antibody or fusion protein. The potential of an antibody-based system for the tight binding of complexes between rare-earth metal ions and the chelator 1,4,7,10-tetraazacyclo­dodecane-N,NN′′,N′′′-tetraacetic acid (DOTA) in biomedical applications was demonstrated with the Fab fragment of the monoclonal antibody (MAb) 2D12.5, which was originally raised against a Y3+·DOTA analog (Corneillie, Whetstone et al., 2003View full citation). This Fab showed high affinity towards MIII·DOTA complexes across the entire lanthanide series, often comparable to, or even better than, that of the original complex with Y3+, as measured by a competitive immunoassay. Of note, while naked lanthanide ions tend to form precipitates under physiological or weakly alkaline pH conditions, or may unspecifically interact with biomolecules, their DOTA complexes are inert and remain highly soluble even under in vivo conditions. However, the precise geometry of metal complexes with this cyclic chelator varies depending on their ionic radius. Indeed, the binding strength between the 2D12.5 Fab and the series of lanthanide ions in complex with DOTA showed a parabolic correlation with optimal affinity near Y3+, corresponding to an effective ionic radius rion ≃ 1.075 Å (for coordination number CN = 9; Shannon, 1976View full citation), and decreasing affinity for larger or smaller ions. This is likely due to changes in the metal-chelate geometry, although X-ray crystallo­graphic analysis of the 2D12.5 Fab bound to DOTA analogs in complex with either Y3+ or Gd3+, two metal ions with very similar ionic radii, indicated only minute structural deviations (Corneillie, Fisher et al., 2003View full citation).

Compared with Fab fragments of antibodies, engineered non-Ig scaffolds, such as Anticalins, which are derived from human lipocalin proteins, offer a smaller size and stable single-chain protein fold as well as improved tissue penetration while enabling high-affinity metal-chelate recognition, which makes them promising alternatives for PET or SPECT imaging. In fact, human lipocalin 2 (Lcn2; also known as neutrophil-gelatinase-associated lipocalin, NGAL), an abundant plasma protein, naturally binds iron-chelate complexes, so-called siderophores (Goetz et al., 2002View full citation). Furthermore, engineered versions of Lcn2 have been developed, dubbed Anticalins, which specifically bind Fe3+ or Ga3+ in complex with the bacterial chelators petrobactin (Dauner et al., 2018View full citation) as well as pyoverdine and pyochelin (Dauner & Skerra, 2020View full citation). Other Anticalins have been engineered to recognize lanthanide complexes with derivatives of diethylenetriaminepentaacetic acid (DTPA; Eggenstein et al., 2014View full citation; Kim et al., 2009View full citation), an acyclic chelator that is frequently used for the preparation of radionuclide conjugates in nuclear medicine (Brechbiel & Gansow, 1991View full citation, 1992View full citation).

Generally, lipocalins are small, soluble secretory proteins found in many organisms, including humans, where they are involved in the transport or storage of a wide range of biomolecules (Schiefner & Skerra, 2015View full citation; Skerra, 2000View full citation). The structural core of lipocalins is highly conserved, featuring a β-barrel formed by eight antiparallel strands with four structurally variable loops at its open end, which can be reshaped to specifically bind novel targets (Beste et al., 1999View full citation). This can be achieved by generating random libraries via targeted mutagenesis and combinatorial selection, resulting in so-called Anticalins, which leverage the stable and versatile lipocalin scaffold to create alternative binding proteins for diagnostic and therapeutic applications (Achatz et al., 2022View full citation; Deuschle et al., 2021View full citation; Gebauer & Skerra, 2012View full citation; Richter et al., 2014View full citation; Rothe & Skerra, 2018View full citation). Compared with conventional antibodies, Anticalins offer several advantages as they are significantly smaller (approximately 20 kDa compared with 150 kDa), which facilitates their cost-efficient production in prokaryotic expression systems such as Escherichia coli. Furthermore, Anticalins exhibit high thermal and chemical stability, which makes them resistant to harsh production and storage conditions. Finally, Anticalins lack an Ig Fc region, thus preventing undesired interactions with cells or the immune system.

In the context of pretargeted radioimmunotherapy and in vivo imaging, there is a growing demand for compact, robust and specific ligand-binding proteins to enhance tumor penetration, accelerate blood clearance and enable flexible exchange between radionuclides (e.g. 68Ga/90Y, 111In/177Lu) while maintaining high affinity for the metal-chelate complexes (Boswell & Brechbiel, 2007View full citation; Burkett et al., 2023View full citation; Goldenberg & Sharkey, 2006View full citation). In this context, Anticalins that have been developed for high affinity towards the rare-earth metal chelates Y3+·DTPA, Tb3+·DTPA and Lu3+·DTPA offer promising tools for in vivo diagnostics and radionuclide therapy (Eggenstein et al., 2014View full citation; Kim et al., 2009View full citation). Another recent application of these Anticalins relates to the PET-tracking of CAR T-cells in lymphoma models using an [18F]-labeled derivative of DTPA charged with a nonradioactive lanthanide metal ion (Morath et al., 2025View full citation).

The initially selected Anticalin variants C26 (Kd ≃ 0.4 nM towards Y3+·DTPA) and L1 were subjected to in vitro affinity maturation, yielding the mutant CL31, which features a fourfold slower off-rate (>2 h dissociation half-life) and improved association kinetics towards several MIII·DTPA complexes (Eggenstein et al., 2014View full citation; Kim et al., 2009View full citation). Further optimization involved four loop mutations, M44E, S86G, P87S and A145T, relative to CL31, resulting in the Anticalin CL31d, conferring superior thermostability and again better MIII·DTPA affinity. Thus, the Anticalin CL31d offers a promising protein reagent for metal-complex binding in nuclear medicine, for example, as part of a bispecific fusion protein or when conjugated to an antibody, such as in the Mabcalin format (Luo et al., 2026View full citation). In this regard, knowledge of the affinities towards DTPA complexes of various lanthanide and related main-group metal ions and a potential dependency on their ionic radii appears relevant. To this end, we here describe a systematic analysis of the binding properties of the Anticalin CL31d for various MIII·DTPA complexes both at the functional and structural level.

In the context of applications in nuclear medicine, potential ion preferences are particularly relevant, encompassing a series of clinically established and emerging diagnostic and therapeutic radiometals. Among these are 68Ga3+ and 43/44Sc3+ for PET imaging (β+ emitters) as well as 111In3+ for SPECT imaging (γ emitter) (Boswell & Brechbiel, 2007View full citation). Furthermore, 153Sm3+, 90Y3+, 161Tb3+, 165Dy3+, 177Lu3+ and 47Sc3+ have been investigated as β emitters (Giese, 2018View full citation), while 161Tb3+ opens perspectives as an Auger electron emitter for targeted radiotherapy (Fricke et al., 2026View full citation). Therefore, we extended the previous characterization of the binding activity of CL31d towards metal-chelate complexes to a panel of 11 different MIII·DTPA complexes, thus covering this series of medically relevant trivalent metal ions.

2. Materials and methods

2.1. Preparation of MIII·DTPA chelate complexes

An equimolar solution of YCl3·6H2O, TbCl3·6H2O, LuCl3·6H2O, GdCl3·6H2O, SmCl3·6H2O, HoCl3, InCl3, ScCl3 (all >99.99%; Sigma–Aldrich, Schnelldorf, Germany), BiCl3, GaCl3 (all >99.99%; Thermo Fisher Scientific, Darmstadt, Germany), DyCl3·xH2O, Ga(NO3)3·xH2O (all >99.99%; Carl Roth, Karlsruhe, Germany) and [(R)-2-amino-3-(4-aminophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diaminepentaacetic acid (p-NH2-BnCHX-A″-DTPA or, in brief, DTPA-NH2; Macrocyclics, Plano, Texas, USA) was mixed (at stoichiometric ratios stated in the text below) in 100 mM ammonium acetate pH 5.0 (Carl Roth) and incubated for 10 min at room temperature. The resulting MIII·DTPA complexes were subsequently used for affinity measurements with the Anti­calin by fluorescence titration.

2.2. Soluble protein production and purification

The Anticalin CL31d (Eggenstein et al., 2014View full citation) was produced in the periplasm of E. coli strain TG1/F (Kim et al., 2009View full citation) using the expression vector pNGAL15 according to published procedures (Gebauer & Skerra, 2012View full citation). Briefly, the bacteria were cultured in 2 l LB medium supplemented with 100 mg l−1 ampicillin at 30°C and agitated in a shake flask at 150 rev min−1 until an OD550 ≃ 2.0 was reached. Recombinant gene expression was then induced by adding 200 µg l−1 anhydrotetracycline (aTc; Acros Organics, Geel, Belgium) for 3 h. The Anticalin was purified from the periplasmic cell extract via affinity chromatography using the Strep-tag II system (Schmidt & Skerra, 2007View full citation). Finally, preparative size-exclusion chromatography (SEC) on a Superdex 75 16/60 GL column (GE Healthcare, Freiburg, Germany) was performed with phosphate-buffered saline (PBS; 4 mM KH2PO4, 16 mM Na2HPO4, 115 mM NaCl pH 7.4) or with 10 mM Tris–HCl, 100 mM NaCl pH 8.0 as running buffers, respectively, for subsequent fluorescence titration or protein crystallization. Protein purity was verified by SDS–PAGE (Fling & Gregerson, 1986View full citation) and protein concentrations were determined by measuring the absorption at 280 nm using a calculated extinction coefficient of 23.045 M−1 cm−1 (Gasteiger et al., 2003View full citation).

2.3. Fluorescence titration

The binding activity of the Anticalin CL31d towards different MIII·DTPA complexes in solution was measured using a FluoroMax-3 spectrofluorimeter (HORIBA Jobin Yvon, Unterhaching, Germany) operated with the FluorEssence software version 3.1. A freshly purified 1 µM protein solution in 2 ml PBS was placed in a quartz cuvette (10 mm path length; Hellma, Mühlheim, Germany) equipped with a tiny magnetic stirrer. The temperature was set to 25°C and, after reaching equilibrium, fluorescence of the protein Tyr/Trp residues was excited at 280 nm. The fluorescence intensity was recorded at 340 nm, corresponding to the emission maximum. A 100 µM solution of the MIII·DTPA complex in 100 mM ammonium acetate pH 5.0 was added stepwise, under stirring, up to a maximum volume of 40 µl (2% of the total sample volume), each time followed by 3 min incubation and measurement of the steady-state fluorescence. To calculate the Kd value, the data were normalized to an initial fluorescence intensity of 100% (corresponding to the plain protein solution, disregarding the subsequent dilution by the small ligand aliquots) and plotted against the total ligand concentration at each titration step. The data were then fitted via nonlinear least-squares regression based on the law of mass action for bimolecular complex formation with the KaleidaGraph software version 4.0 (Synergy, Reading, Pennsylvania, USA) using a published formula (Breustedt et al., 2006View full citation).

2.4. Crystallization of CL31d with DTPA-NH2 in complex with different metal ions

The purified Anticalin CL31d was concentrated with a Vivaspin concentrator (10 kDa cutoff; Sartorius, Göttingen, Germany) and sterile-filtered with Costar Spin-X centrifuge units (0.45 µm; Sigma–Aldrich). For complex formation prior to crystallization, the corresponding solution of MIII·DTPA-NH2 was added to the protein solution in a 1.3:1 molar ratio (metal-chelate ligand:protein) for lanthanide ions and in a 3:1 molar ratio for main-group metal ions. Prior to this, metal ions were mixed with DTPA-NH2 in a 10:1 molar ratio (metal:DTPA), except for Bi3+ and Dy3+, which were mixed with DTPA-NH2 in a 1:1 ratio. The final protein concentration was adjusted to 15–19 mg ml−1. Altogether, six different MIII·DTPA-NH2–Anticalin complexes were crystallized (Table 1[link]) using the hanging-drop vapor-diffusion method. The drops consisted of 1 µl MIII·DTPA-NH2–Anticalin solution and 1 µl precipitant solution (for Lu3+, Tb3+, Sc3+, Bi3+ and Ga3+) or of 1.25 µl MIII·DTPA-NH2–Anticalin and 1.25 µl precipitant solution (for Dy3+). The protein–ligand complexes were crystallized at 20°C using PEG 3350 and KH2PO4 as precipitants. Crystals grown at high PEG concentrations [34–36%(w/v)] were directly harvested from the droplets and immediately frozen in liquid nitrogen (for Bi3+, Lu3+ and Sc3+), whereas those from droplets with lower PEG concentrations [19–27%(w/v)] were first transferred into the respective precipitant buffer supplemented with 20%(v/v) glycerol (for Tb3+ and Dy3+) or 25%(v/v) glycerol (for Ga3+) prior to freezing (Supplementary Table S2).

Table 1
X-ray data-collection and refinement statistics for CL31d–MIII·DTPA-NH2 complexes

Values in parentheses are for the highest resolution shell.

  Lu3+·DTPA-NH2 Dy3+·DTPA-NH2 Tb3+·DTPA-NH2 Sc3+·DTPA-NH2 Bi3+·DTPA-NH2 H2O·DTPA-NH2
Crystal data
 Space group P41212 [No. 92] P41212 [No. 92] P41212 [No. 92] P41212 [No. 92] P41212 [No. 92] P41212 [No. 92]
a, b, c (Å) 60.1, 60.1, 110.4 61.4, 61.4, 118.0 60.3, 60.3, 110.7 59.6, 59.6, 110.1 60.2, 60.2, 111.1 60.1, 60.1, 110.7
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
 Molecules per asymmetric unit 1 1 1 1 1 1
Data collection
 Wavelength (Å) 0.97630 1.00001 0.97630 0.97620 0.97630 0.97620
 Resolution range (Å) 60.07–1.45 61.25–1.80 110.70–1.60 42.14–1.60 55.56–1.60 60.10–1.50
 〈I/σ(I)〉 9.0 (2.0) 4.3 (1.2) 14.0 (2.1) 17.7 (2.1) 14.6 (2.0) 25.8 (2.1)
Rmeas (%) 8.5 (71.5) 10.8 (67.0) 6.4 (92.0) 4.0 (79.8) 5.3 (72.1) 3.2 (77.5)
 Unique reflections 36362 21548 26313 26141 26684 32903
 Multiplicity 3.6 (3.7) 12.6 (12.6) 5.9 (6.0) 3.6 (3.7) 3.7 (3.6) 4.4 (4.5)
 Completeness (%) 99.0 (99.5) 99.9 (100.0) 94.6 (95.2) 96.7 (98.2) 96.0 (98.9) 98.7 (98.8)
Refinement
Rcryst/Rfree (%) 17.0/19.6 19.2/22.7 17.4/20.1 18.3/21.8 17.4/20.1 17.5/20.3
 Protein atoms 1425 1406 1418 1436 1402 1419
 Ligand atoms 39 39 45 [+6 in glycerol] 39 39 39
 Ions 2 [Lu3+, K+] 2 [Dy3+, K+] 2 [Tb3+, K+] 2 [Sc3+, K+] 4 [Bi3+, 2 K+, Mathematical equation] 1 [K+]
 Solvent atoms 120 95 107 133 147 131 [+1 in DTPA]
 Average B factor (Å2) 29.3 35.2 31.4 30.9 28.0 26.2
 Geometry
  R.m.s.d., bond lengths (Å) 0.008 0.009 0.009 0.010 0.010 0.011
  R.m.s.d., angles (°) 1.479 1.659 1.661 1.734 1.732 1.923
 Ramachandran analysis            
  Core (%) 92.8 92.0 92.1 90.9 92.6 92.8
  Allowed (%) 5.3 6.0 5.9 6.5 5.4 5.9
  Generously allowed (%) 0.7 0.7 0.7 0.6 0.7 0.0
  Disallowed (%) 1.3 1.3 1.3 1.9 1.3 1.3
Rfree is Rcryst for 5% of the reflections that were randomly selected and excluded from refinement (Brünger, 1997View full citation).

2.5. Data collection and model building

Synchrotron X-ray diffraction data sets for the different protein crystals (Table 1[link]) were collected on beamline P13 (for Lu3+, Tb3+, Sc3+, Bi3+ and Ga3+) of the PETRA III storage ring operated by EMBL (DESY, Hamburg, Germany) and on beamline X06SA (for Dy3+) of the Swiss Light Source (SLS; Paul Scherrer Institute, Villigen, Switzerland). The data were either processed with XDS and XSCALE (Kabsch, 2010View full citation; for Lu3+, Tb3+, Sc3+, Bi3+ and Ga3+) or with MOSFLM and SCALA from CCP4 (Agirre et al., 2023View full citation; for Dy3+). Molecular replacement was performed with Phaser (Evans & McCoy, 2008View full citation) using the coordinate set of the Lcn2 variant CL31 with the bound chelate complex between Y3+ and a Tris adduct of p-SCN-Bn-CHX-A″-DTPA (PDB entry 4iax). The initial structure of the MIII·DTPA-NH2 ligand was adopted from the same coordinate set. Atomic models were built with Coot (Emsley & Cowtan, 2004View full citation) and refined with REFMAC5 (from CCP4) in iterative cycles. Water molecules were added with ARP/wARP (Langer et al., 2008View full citation). The resulting models were rectified using the PDB-REDO server (Joosten et al., 2014View full citation) and validated using PROCHECK (Laskowski et al., 1993View full citation) and the MolProbity server (Williams et al., 2018View full citation). Protein–ligand interactions were analyzed with PISA (Krissinel & Henrick, 2007View full citation). Graphics and structural alignments were prepared with PyMOL (Schrödinger, New York, USA). The atomic coordinates and structure factors of the refined structures have been deposited in the Protein Data Bank (PDB), Research Collaboratory for Structural Bioinformatics (RCSB; Rutgers University, New Brunswick, New Jersey, USA) under accession codes 28xi (H2O·DTPA-NH2), 28xn (Lu3+·DTPA-NH2), 28xl (Tb3+·DTPA-NH2), 28xm (Sc3+·DTPA-NH2), 28xk (Bi3+·DTPA-NH2) and 28xj (Dy3+·DTPA-NH2).

3. Results and discussion

3.1. Investigation of the affinities between the Anticalin CL31d and different MIII·DTPA-NH2 complexes by fluorescence titration

Previous work had demonstrated the selection and structural characterization of Anticalins that bind metal-chelate complexes formed between DTPA-NH2 and certain lanthanide ions (Kim et al., 2009View full citation), such as Y3+, Tb3+ and Lu3+, whose radioisotopes are widely used in nuclear medicine for diagnostic imaging and targeted radiotherapy (Milenic et al., 2004View full citation; Boswell & Brechbiel, 2007View full citation; Goldenberg & Sharkey, 2006View full citation; Han & Lee, 2026View full citation). Rational mutagenesis led to the improved Anticalin CL31d, showing high-affinity recognition of the hapten-like metal-chelate complex, with a dissociation constant (Kd) of 4.6 nM, measured for Y3+·DTPA-NH2 via fluorescence titration, and of 0.5 nM, measured for a Y3+·DTPA-RNaseA conjugate via real-time surface plasmon resonance (SPR) spectroscopy (Eggenstein et al., 2014View full citation). Building upon the previously described crystal structure of the parental variant CL31 with a bound Y3+·DTPA chelate derivative (PDB entry 4iax), the present investigation focused on the engineered mutant CL31d with bound chelate ligand DTPA-NH2 in complex with different trivalent metal ions (Fig. 1[link]).

[Figure 1]
Figure 1
Structures of the metal-chelate complexes and their binding to the Anticalin. (a) Formation of an octadentate MIII·DTPA-NH2 complex and its chemical configuration. (b) Binding of the metal chelate to the ligand pocket of the Anticalin CL31d at the open end of the β-barrel.

The Anticalin CL31d was produced in the soluble folded state, including one structural disulfide bridge (Eggenstein et al., 2014View full citation; Schiefner & Skerra, 2015View full citation), in the periplasm of E. coli and purified via the Strep-tag II (Schmidt & Skerra, 2007View full citation), followed by size-exclusion chromatography (SEC). Its binding activity towards different MIII·DTPA-NH2 chelate complexes in solution was analyzed via fluorescence titration using the ligand-quenching effect on the emission by Tyr/Trp side chains of the protein for read-out (Eggenstein et al., 2014View full citation; Kim et al., 2009View full citation). In this manner, 11 different MIII ions of the lanthanide series and adjacent main-group III and V elements, with ionic radii ranging from 0.62 to 1.03 Å, in complex with the DTPA-NH2 chelate ligand were investigated (Fig. 2[link], Table 2[link]).

Table 2
Kd values measured via fluorescence titration for the Anticalin CL31d with different metal ions in complex with DTPA-NH2 as a function of their ionic radii (depending on the coordination number, CN = 6–9; Shannon, 1976View full citation)

Central ion Mathematical equation (Å) Mathematical equation (Å) Mathematical equation (Å) Kd (nM)
Bi3+ 1.03 1.17 47.8 ± 1.8
Sm3+ 0.96 1.13 2.3 ± 0.8
Gd3+ 0.94 1.11 0.8 ± 0.4
Tb3+ 0.92 1.09 1.9 ± 0.7
Dy3+ 0.91 1.08 1.3 ± 0.5
Y3+ 0.90 1.07 1.0 ± 0.3
Ho3+ 0.90 1.07 2.4 ± 1.0
Lu3+ 0.86 1.03 1.7 ± 0.7
In3+ 0.80 0.92 2.2 ± 0.9
Sc3+ 0.75 0.87 2.3 ± 1.1
Ga3+ 0.62 1.05 15.3 ± 1.9
(H2O) (12.1 ± 0.9)
[Figure 2]
Figure 2
Exemplary fluorescence titration of the Anticalin CL31d with (a) Ho3+·DTPA-NH2 and (b) Bi3+·DTPA-NH2. The ligand solution was added stepwise to an approximately 1 µM protein solution in PBS, and the protein Tyr/Trp fluorescence upon excitation at 280 nm was measured at 340 nm. Data were subjected to curve fitting according to the law of mass action for bimolecular complex formation. The equivalence point (0.85 or 1.10 µM, respectively, resulting from the curve fit) is indicated by a small vertical arrow. Fluorescence titration of CL31d was also performed with DTPA-NH2 in complex with Sm3+, Gd3+, Tb3+, Dy3+, Y3+, Lu3+, In3+, Sc3+ and Ga3+, and without metal ion (for the resulting Kd values, see Table 2[link]).

According to the measured Kd values, CL31d exhibits strong and surprisingly uniform affinity, in the range 0.8–2.4 nM, towards the DTPA-NH2 chelator charged with different trivalent metal ions from the lanthanide series (Table 2[link], Fig. 3[link]), in particular those with ionic radii close to 0.90 Å (0.75–0.96 Å), as reported for coordination number (CN) = 6 (Shannon, 1976View full citation). In contrast, fluorescence titration with DTPA-NH2 complexes of the main-group metals Ga3+ (Kd = 15.3 nM; rion = 0.62 Å) and Bi3+ (Kd = 47.8 nM; rion = 1.03 Å) indicated 6- to 60-fold lower affinities, also in relation to those main-group metals whose ionic radii are more similar to the lanthanides, such as Sc3+ (0.75 Å) and In3+ (0.80 Å). Regarding potential applications of the corresponding radionuclides in nuclear medicine, this suggests that any clinically useful metal ion with a radius around 0.90 Å may be employed as a DTPA-NH2 chelate complex with the Anti­calin CL31d. This would relate, for example, to the radioisotopes 90Y3+, 177Lu3+, 161Tb3+, 47Sc3+, 153Sm3+, 165Dy3+ and 166Ho3+ for therapy or to 111In3+, 43/44Sc3+ and 153Gd3+ for in vivo diagnostics (Boswell & Brechbiel, 2007View full citation; Giese, 2018View full citation; Han & Lee, 2026View full citation; Sadler et al., 2022View full citation; Van Laere et al., 2024View full citation).

[Figure 3]
Figure 3
Affinities of the MIII·DTPA-NH2 chelate complexes towards the Anti­calin CL31d plotted against the respective ionic radius of the metal (CN = 6). Spheres correspond to lanthanide elements, while squares represent main-group metals; filled symbols denote those metal ions whose complexes with an Anticalin were elucidated by X-ray crystallography. The curve fit of the data points from fluorescence titration measurements is based on a spline function.

In a preceding study on the 2D12.5 Fab fragment, Corneillie and coworkers reported a parabolic affinity relationship for the binding activity towards DOTA–lanthanide complexes (Corneillie, Whetstone et al., 2003View full citation), with a peak for metal ions with an ionic radius (rion) of approximately 1.115 Å (Gd3+, 1.107 Å; Eu3+, 1.120 Å) described for CN = 9 (corresponding to 0.944 Å for Gd3+ at CN = 6; see Table 2[link]). Their findings indicated that smaller ions (e.g. Lu3+) contract the complex with the macrocycle, while larger ones (e.g. La3+) expand it. This likely leads to a distortion of the ligand geometry by displacing hydrophobic methylene groups from the binding pocket of the Fab and thereby increasing the free-energy penalty (ΔΔG; Corneillie, Fisher et al., 2003View full citation).

In comparison, we observed a surprisingly flat affinity profile of the Anticalin CL31d for DTPA-NH2 chelate complexes with trivalent metal ions with ionic radii in the range from 0.75 to 0.96 Å, which suggests a more relaxed dependence (Fig. 3[link]). In fact, the branched linear chemical configuration of the DTPA chelator and its resulting compact eight-coordinated complex structures, with five carboxylate O atoms and three N atoms as donors and, optionally, one additional H2O molecule as a ligand, appears to be more tolerant towards distortions caused by the size of the central ion, resulting in minimal geometric variation (Fig. 4[link]).

[Figure 4]
Figure 4
X-ray structural analysis of different MIII·DTPA-NH2 chelate complexes bound to the Anticalin CL31d. (a) Superposition of the different CL31d structures with bound DTPA-NH2 chelate complexes of Bi3+ (cyan C atoms), Tb3+ (green), Dy3+ (orange), Lu3+ (yellow), Sc3+ (salmon) and the previously published Y3+·DTPA-SCN complex (white; PDB entry 4iax), as well as the metal-free DTPA-NH2 (purple; from co-crystallization with Ga3+) using a set of 58 structurally conserved Cα atoms of the lipocalin scaffold. (b) Individual MIII·DTPA-NH2 complexes from the co-crystal structures with the Anticalin CL31d or CL31 together with the metal-coordinating water molecule (dashed lines indicate the eightfold or ninefold metal coordination). (c) Exemplary 2FoFc electron densities for the DTPA-NH2 complexes of Sc3+ (left) and Bi3+ (center) in comparison with the metal-free chelate ligand (obtained in the presence of Ga3+), which harbors a water molecule at the position of the central ion (right). The 2FoFc electron densities are contoured at 1σ in blue for DTPA-NH2 and additonally at 3σ in yellow-orange for the central ion or water molecule.

Of note, for analysis across the range of metal ions investigated in the present study (Fig. 3[link]) we used rion values reported for CN = 6 (Shannon, 1976View full citation), since non-lanthanide metal ions (in particular In3+, Sc3+ and Ga3+) lack standardized values for CN = 9, as they predominantly coordinate 6–8 ligand donors and rarely adopt ninefold coordination (Lau et al., 2006View full citation; Meehan et al., 1999View full citation; Shannon, 1976View full citation). Nevertheless, the relative trend in changes of rion between the different elements is similar, regardless of the specific CN applied (see Table 2[link]). Indeed, when plotting the affinities between the Anticalin CL31d and the different MIII·DTPA-NH2 chelate complexes against the ionic radii reported for CN = 9, to the extent available, a nearly identical curve was obtained (not shown).

3.2. Structural analysis of MIII·DTPA-NH2 chelate complexes bound to the Anticalin CL31d and influence of the central ion on the geometry

To obtain detailed insight into how the central ion of lanthanides and chemically related metals influences the configuration of the chelate complex and its interactions within the engineered lipocalin pocket, we determined X-ray structures of CL31d co-crystallized with the DTPA-NH2 complexes of Bi3+, Tb3+, Dy3+, Lu3+, Sc3+ and Ga3+ at high resolution (1.5–1.8 Å; Table 1[link]; Fig. 4[link]). These metals span ionic radii from 0.62 to 1.03 Å (CN = 6) and include clinically relevant ions such as Tb3+ and Lu3+, whose radioisotopes (161Tb3+ and 177Lu3+, respectively) have found increasing use in targeted radionuclide therapy (Van Laere et al., 2024View full citation; Trejtnar et al., 2025View full citation). Furthermore, the main-group metal ions Bi3+ and Ga3+, with 213Bi3+ of relevance as a therapeutic α emitter (Nawar et al., 2025View full citation) and 68Ga3+ as a β+ emitter for PET imaging (Morath et al., 2023View full citation), were chosen due to their significantly larger/smaller ionic radii as well as their considerably lower measured affinities towards the Anticalin when applied in complex with DTPA-NH2 (Table 2[link]).

Across all six structures, both the binding protein and the metal-chelate ligand accommodated in its pocket revealed remarkably conserved conformations. Superposition of the β-barrel core and non-engineered loops using 58 structurally conserved Cα atoms (Achatz et al., 2022View full citation) yielded an average root-mean-square deviation (r.m.s.d.) of only 0.095 Å relative to the parental CL31–Y·DTPA-SCN structure (PDB entry 4iax), which moreover deviates by four amino-acid substitutions (M44E/S86G/P87S/A145T; Eggenstein et al., 2014View full citation). Similarly, individual superposition of the different DTPA-NH2 chelate ligands (without the central ion) led to an r.m.s.d. of 0.14 Å, on average, for 39 atoms (Fig. 5[link]). In all complexes, the trivalent metal ion was seen to be encapsulated by the multidentate DTPA chelator, whose nitrogen and carboxylate donor groups form the characteristic MIII·DTPA core and also engage in a network of hydrogen bonds and salt bridges with polar and charged side chains that line the ligand pocket of the protein.

[Figure 5]
Figure 5
Correlation between the radius of the central ion and the overall geometry of the Anticalin-bound metal-chelate complex. (a) Superposition of the six different MIII·DTPA-NH2 complexes via the central ion to illustrate the minute structural influence of the ionic radius: Bi3+·DTPA-NH2 (cyan C atoms), Tb3+·DTPA-NH2 (green), Dy3+·DTPA-NH2 (orange), Y3+·DTPA-NH2 (white), Lu3+·DTPA-NH2 (yellow) and uncomplexed DTPA (purple). (b) Sum of the metal–ligand distances to eight donor atoms (5 O + 3 N) plotted against the ionic radii (CN = 6). (c, d) Superposition of the Sc3+·DTPA-NH2 complex (salmon) and of the empty DTPA-NH2 chelator (purple; harboring a central water molecule, which is obscured here, and one peripherally associated water molecule), respectively, with the published In3+·DTPA complex (light blue) from the Cambridge Structural Database (CSD entry MOQVOD). Contacts with the coordinating N and O atoms and the water molecule are indicated by dashed black lines.

Similar to the crystal structure of the parental CL31–Y·DTPA-SCN complex, the MeIII·DTPA core group is bound among the side chains of residues Gln33, Arg36, Thr52 and Gln54 in loop 1, Val66, Ala68, Arg70, Glu77, Tyr78 and Leu79 in loop 2, Tyr106 and Phe123 in loop 3 as well as Ser136 in loop 4, which together form the four hypervariable loops of the lipocalin scaffold (Achatz et al., 2022View full citation; Skerra, 2000View full citation). The shorter p-NH2-benzyl linker, compared with the Tris-quenched Y3+·DTPA-SCN employed in the preceding crystallo­graphic study (Eggenstein et al., 2014View full citation), consistently docks against the ridge formed by the side chains of Leu79 as well as Arg70 and Glu77. Likewise, the chiral cyclohexylene group was observed to pack against the hydrophobic residues Val66, Ala68, Leu79, Met81 and Phe83 in all complexes of CL31d-bound MIII·DTPA-NH2, including the previously elucidated CL31–Y3+·DTPA-SCN complex. The chelate arms of the DTPA moiety maintain identical hydrogen bonds to Gln33 (Oɛ1, Nɛ2), Thr52 (Oγ), Gln54 (Nɛ2), Tyr106 (OH) and Ser136 (Oγ) at distances of 2.7–3.5 Å.

Regarding the metal ion coordination geometry, all lanthanide complexes exhibit uniform ninefold coordination by the following donor groups/atoms: five (deprotonated) carboxylate O atoms, three tertiary N atoms and one bound water molecule. Notably, in the co-crystal structure with Sc3+, which represents a smaller main-group ion (Mathematical equation = 0.75 Å) two rows above La3+ in the periodic table of the elements, the water ligand is missing (Fig. 5[link]c), resulting in an eightfold coordination with a distorted Archimedian antiprismatic configuration, similar to that described in the seminal crystallographic analysis of the Na2In(DTPA)·7H2O salt (Maecke et al., 1989View full citation). Thus, it appears that all metal ions larger than Sc3+ and In3+ (Mathematical equation = 0.80 Å) investigated here, in particular those belonging to the lanthanide series, exhibit an expanded coordination sphere where a water molecule from the solvent occupies the ninth position. Obviously, this molecular behavior is independent of the precise electronic configuration of the central metal ion, as it is observed for four different lanthanides and even for the main-group metal ion Bi3+ (which has a fully occupied shell of d and f electrons).

Unexpectedly, in the crystallographic analysis performed for the CL31d–MIII·DTPA-NH2 complex in the presence of Ga3+, which shows an even smaller ionic radius (Mathematical equation = 0.62 Å) than Sc3+ (see Table 2[link]), no bound metal ion was detectable; instead, the electron-density map revealed a spherical signal characteristic of a discrete water molecule (Fig. 4[link]b and 4[link]c). This situation did not change in repeated co-crystallization trials using a threefold excess of DTPA-NH2 and up to a tenfold excess of GaCl3 relative to the Anticalin protein. Indeed, confirmatory fluorescence titration measurements underlined an incomplete chelation: use of `Ga3+·DTPA-NH2' as a ligand indicated a Kd value of 15.3 ± 1.9 nM, while a fluorescence titration of CL31d with empty DTPA-NH2 (without metal ion added) resulted in Kd = 12.1 ± 0.9 nM, both values being statistically indistinguishable (Supplementary Fig. S1). This finding aligns with the chemical properties known for Ga3+: it forms weak, kinetically labile complexes with chemically related cyclic chelators, such as DOTA (logK ≃ 22–26, compared with 27.5 for Lu3+; Kubícek et al., 2010View full citation), but it favors a (distorted) octahedral (hexadentate) coordination over the octadentate complex formation typical for DTPA, due to its small radius and pronounced tendency to hydrolysis.

Indeed, a previous 13C-NMR analysis of the Ga(DTPA)2− complex indicated that while this complex appeared to be stable in neutral solution, the central Ga3+ ion adopts its preferred octahedral coordination, with only three COO groups engaged (together with the three N atoms of DTPA) and two COOH groups in an uncomplexed state (Maecke et al., 1989View full citation). Obviously, the resulting peculiar geometry of this chelate complex is not compatible with binding to the ligand pocket of the Anticalin CL31d. On the other hand, from the perspective of the engineered lipocalin, it is astonishing that this artificial binding protein appears to recognize the empty chelator with relatively strong affinity and in a conformation that is amenable to tight metal-ion complexation (Figs. 4[link]b and 4[link]c). This might be an effect of the (chiral) cyclohexylene moiety introduced into the backbone of the otherwise acyclic DTPA chelator employed here, which is known to favor a complexation-competent conformation, leading to kinetic inertness of Y3+ (and related metal ion) complexes in comparison with plain DTPA (McMurry et al., 1998View full citation). In fact, a direct structural comparison of the protein-bound Sc3+·DTPA-NH2 complex solved in the present study with the previously published Na2In(DTPA)·7H2O salt (Fig. 5[link]c) proves that the rigidification of the DTPA backbone by the cyclohexylene group does not affect the octadentate complex geometry.

3.3. Detailed analysis of the ligand geometry in the CL31d-bound MIII·DTPA-NH2 complexes

Mutual comparison of the different Anticalin-bound metal-chelate complexes did not reveal noticeable changes due to the identity or ionic radius of the individual metals investigated. In fact, a superposition of the DTPA-NH2 chelator across all complexes yielded very small r.m.s.d. values of 0.13–0.39 Å for a total of 39 equivalent atom pairs (Fig. 5[link]a). The Sc3+·DTPA-NH2 and H2O·DTPA-NH2 structures showed slightly larger deviations (0.39 and 0.26 Å, respectively), which were mostly attributable to contracted carboxylate arms (Supplementary Table S1) and the missing additional water ligand or central ion, respectively. Nevertheless, the orientation of the DTPA-NH2 molecule within the Anticalin pocket remained essentially invariant, as shown by conserved protein side-chain positions and hydrogen-bonding patterns involving residues Ser87, Asp89 and Tyr132 (see above).

For further analysis, we quantified the individual metal–ligand distances to the eight coordinating atoms of the DTPA-NH2 chelator (5 O + 3 N). Again, the resulting pattern (Supplementary Table S1) revealed only minute differences, also when including the additional water ligand. This means that the overall geometry of the MIII·DTPA-NH2 complexes is mostly determined by the chemical constitution of the octadentate chelator, which acts as a rigid cage, rather than by the ionic radius of the central metal ion. However, when adding up the individual metal–donor distances, the small individual changes accumulated and a linear scaling with the ionic radius became apparent (Fig. 5[link]b), with a Pearson correlation coefficient R = 0.948. A similar picture appeared when including the water ligand that is present in the complexes (except for Sc3+; not shown).

Interestingly, only for the largest ion tested, Bi3+ (1.03 Å), were structural deviations in the Anticalin-bound metal-chelate complex detectable. The average metal–donor distances were elongated by 0.12 Å (see Supplementary Table S1), while the water-mediated hydrogen-bonding pattern around the DTPA chelate remained essentially conserved. The position of a single bridging water molecule between the carboxylate oxygens O2 and O5 differed by about 0.1 Å upon superposition with the H2O·DTPA-NH2 complex. These significant structural perturbations provide a rationale for the approximately 60-fold weaker affinity (Kd = 47.8 nM) of CL31d towards the DTPA-NH2 complex with the main-group ion Bi3+ relative to the lanthanide ions. At the other end of the series of metal ions with differing sizes, the cumulated metal–donor distances revealed the smallest value for the main-group metal ion Sc3+ (18.21 Å versus 19.19 Å for Lu3+, the smallest lanthanide investigated). Nevertheless, Sc3+·DTPA-NH2 retained a high affinity towards the Anticalin (Kd = 2.3 nM), despite the missing additional water ligand, thus demonstrating a broad tolerance of its binding pocket towards variation in ionic radius as long as the gross geometry of the chelate complex is retained.

The essentially linear correlation between the sum of the metal–donor distances and the ionic radii of the MIII·DTPA-NH2 chelate complexes (Fig. 5[link]b, Supplementary Table S1) is in agreement with the conserved molecular recognition by the Anticalin CL31d, revealing a broad plateau in the measured affinities for Mathematical equation values 0.75–0.95 Å (Fig. 3[link]). This contrasts with the binding properties described for antibodies directed against metal-chelate complexes, which typically display either a parabolic affinity pattern depending on the ionic radius or more extreme metal specificity. For instance, the 2D12.5 Fab exhibits moderate cross-reactivity among the series of lanthanide–DOTA complexes (optimal near 1.12 Å, CN = 9). In this case, smaller ions contract while larger ions expand the cyclic chelator, leading to steric strain with the acetate side chains (r.m.s.d. = 0.45 Å between Y3+·DOTA and Gd3+·DOTA; PDB entries 1nc2 and 1nc4; Corneillie, Fisher et al., 2003View full citation). Conversely, the MAb CHA255 directed against In3+·benzyl-EDTA shows a >104-fold preference for the complex with In3+ compared with other metal ions with similar radius, such as Fe3+ and Cd2+ (Love et al., 1993View full citation). This is likely due to the unique axial coordination of In3+ by the Nɛ atom of His H95 in the heavy-chain variable domain (Nɛ–In, 2.4 Å; PDB entry 1ind), which is lost with other metal ions because the chelate adopts a slightly different conformation that shields the central ion from interaction with this His side chain (Delehanty et al., 2003View full citation). Similarly, the MAb 2C12 recognizes Pb2+·CHX-A′′-DTPA with 20–40 000-fold selectivity over different radius-matched metal ions (Khosraviani et al., 2000View full citation).

4. Conclusions

This study demonstrates that the engineered Anticalin CL31d exhibits robust binding of MIII·DTPA-NH2 chelate complexes across a series of trivalent metal ions spanning ionic radii of 0.75–1.03 Å with high affinities throughout (Kd = 0.8–2.4 nM). The mode of molecular recognition is surprisingly tolerant towards central ions with varying size and d/f-electron configuration, covering clinically relevant lanthanides with rion ≃ 0.90 Å, such as Y3+, Lu3+, Tb3+ and Dy3+, as well as In3+ and Sc3+. Only the DTPA complex of Bi3+, with a rather large rion = 1.03 Å, shows significantly weaker binding, whereas that of Ga3+, with an extremely small rion = 0.62 Å, assumes different chelate geometry and, thus, is no longer recognized by the Anticalin.

High-resolution crystal structures (1.5–1.8 Å) reveal nearly invariant geometries for the MIII·DTPA-NH2 chelate complexes when tightly bound by the Anticalin, which contrasts with all antibodies directed against metal-chelate complexes that have been described so far, in particular those involving the cyclic DOTA chelator. In this context, the partially flexible backbone of the acyclic chelate ligand CHX-A″-DTPA, with the exception of the cyclohexylene moiety, enables chelate presentation of metal ions with radii across a considerable range while preserving molecular recognition by the Anticalin with low-nanomolar affinity.

These findings establish the Anticalin CL31d as a versatile non-immunoglobulin protein module for in vivo imaging, as recently demonstrated for the membrane-anchored DTPA receptor (Morath et al., 2025View full citation) and, potentially, for pretargeted radionuclide delivery in the future (Goldenberg et al., 2012View full citation). Generally, in the area of theranostics (Burkett et al., 2023View full citation) the flexible exchange of radioisotopes, for example 90Y3+, 177Lu3+ and 161Tb3+ for tumor therapy or 111In, 43Sc3+ and 68Ga3+ for in vivo diagnostics, offers a crucial advantage. Apart from the low nanomolar avidity, the small size (∼20 kDa) of the Anticalin and its constitution as a robust single-chain protein render it beneficial for the construction of fusion proteins, either to directly label cells at their surface (Morath et al., 2025View full citation) or to generate bispecific antibodies such as the Mabcalin format (Luo et al., 2026View full citation; Wachter et al., 2023View full citation). Future work should validate the application of radiolabeled chelates in vivo and explore different linker modalities to broaden the utility of the Anticalin CL31d for engineered protein theranostics.

Acknowledgements

The authors wish to thank Dr Volker Morath for inspiring discussions, Dr Markus R. Anneser for expert chemical support, Stefan Achatz for ESI-MS measurements and Professor Michael Groll and Dr Eva Huber, both at the TUM School of Natural Sciences, for X-ray diffraction data collection on DESY beamline P14 (Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany) under grants No. MX-940 and MX-970, and on beamline X06SA of the Swiss Light Source (SLS; Paul Scherrer Institute, Villigen, Switzerland) under grant No. 20222274. Open access funding enabled and organized by Projekt DEAL.

Funding information

This work was financially supported through the Federal State of Bavaria and the Deutsche Forschungsgemeinschaft (DFG) by providing the ESI Q-TOF LC-MS instrument in frame of their Major Research Instrumentation Programme (Grant No. INST 95/1734-1; DFG Project No. 505114086).

References

Return to citationAchatz, S., Jarasch, A. & Skerra, A. (2022). J. Struct. Biol. X, 6, 100054.  Web of Science PubMed Google Scholar
Return to citationAgirre, J., Atanasova, M., Bagdonas, H., Ballard, C. B., Baslé, A., Beilsten-Edmands, J., Borges, R. J., Brown, D. G., Burgos-Mármol, J. J., Berrisford, J. M., Bond, P. S., Caballero, I., Catapano, L., Chojnowski, G., Cook, A. G., Cowtan, K. D., Croll, T. I., Debreczeni, J. É., Devenish, N. E., Dodson, E. J., Drevon, T. R., Emsley, P., Evans, G., Evans, P. R., Fando, M., Foadi, J., Fuentes-Montero, L., Garman, E. F., Gerstel, M., Gildea, R. J., Hatti, K., Hekkelman, M. L., Heuser, P., Hoh, S. W., Hough, M. A., Jenkins, H. T., Jiménez, E., Joosten, R. P., Keegan, R. M., Keep, N., Krissinel, E. B., Kolenko, P., Kovalevskiy, O., Lamzin, V. S., Lawson, D. M., Lebedev, A. A., Leslie, A. G. W., Lohkamp, B., Long, F., Malý, M., McCoy, A. J., McNicholas, S. J., Medina, A., Millán, C., Murray, J. W., Murshudov, G. N., Nicholls, R. A., Noble, M. E. M., Oeffner, R., Pannu, N. S., Parkhurst, J. M., Pearce, N., Pereira, J., Perrakis, A., Powell, H. R., Read, R. J., Rigden, D. J., Rochira, W., Sammito, M., Sánchez Rodríguez, F., Sheldrick, G. M., Shelley, K. L., Simkovic, F., Simpkin, A. J., Skubak, P., Sobolev, E., Steiner, R. A., Stevenson, K., Tews, I., Thomas, J. M. H., Thorn, A., Valls, J. T., Uski, V., Usón, I., Vagin, A., Velankar, S., Vollmar, M., Walden, H., Waterman, D., Wilson, K. S., Winn, M. D., Winter, G., Wojdyr, M. & Yamashita, K. (2023). Acta Cryst. D79, 449–461.  Web of Science CrossRef IUCr Journals Google Scholar
Return to citationBeste, G., Schmidt, F. S., Stibora, T. & Skerra, A. (1999). Proc. Natl Acad. Sci. USA, 96, 1898–1903.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationBoswell, C. A. & Brechbiel, M. W. (2007). Nucl. Med. Biol. 34, 757–778.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationBrechbiel, M. W. & Gansow, O. A. (1991). Bioconjug. Chem. 2, 187–194.  CrossRef PubMed CAS Google Scholar
Return to citationBrechbiel, M. W. & Gansow, O. A. (1992). J. Chem. Soc. Perkin Trans. 1, pp. 1173–1178.  CrossRef Google Scholar
Return to citationBreustedt, D. A., Schönfeld, D. L. & Skerra, A. (2006). Biochim. Biophys. Acta, 1764, 161–173.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationBrünger, A. T. (1997). Methods Enzymol. 276, 558–580.  CAS PubMed Google Scholar
Return to citationBurkett, B. J., Bartlett, D. J., McGarrah, P. W., Lewis, A. R., Johnson, D. R., Berberoğlu, K., Pandey, M. K., Packard, A. T., Halfdanarson, T. R., Hruska, C. B., Johnson, G. B. & Kendi, A. T. (2023). Radiol. Imaging Cancer, 5, e220157.  CrossRef PubMed Google Scholar
Return to citationCorneillie, T., Fisher, A. & Meares, C. (2003). J. Am. Chem. Soc. 125, 15039–15048.  CrossRef PubMed CAS Google Scholar
Return to citationCorneillie, T. M., Whetstone, P. A., Fisher, A. J. & Meares, C. F. (2003). J. Am. Chem. Soc. 125, 3436–3437.  CrossRef PubMed CAS Google Scholar
Return to citationDauner, M., Eichinger, A., Lücking, G., Scherer, S. & Skerra, A. (2018). Angew. Chem. Int. Ed. 57, 14619–14623.  Web of Science CrossRef CAS Google Scholar
Return to citationDauner, M. & Skerra, A. (2020). ChemBioChem, 21, 601–606.   CrossRef CAS PubMed Google Scholar
Return to citationDelehanty, J. B., Jones, R. M., Bishop, T. C. & Blake, D. A. (2003). Biochemistry, 42, 14173–14183.  CrossRef PubMed CAS Google Scholar
Return to citationDeuschle, F. C., Ilyukhina, E. & Skerra, A. (2021). Expert Opin. Biol. Ther. 21, 509–518.  CrossRef CAS PubMed Google Scholar
Return to citationEggenstein, E., Eichinger, A., Kim, H. J. & Skerra, A. (2014). J. Struct. Biol. 185, 203–214.  CrossRef CAS PubMed Google Scholar
Return to citationEmsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132.  Web of Science CrossRef CAS IUCr Journals Google Scholar
Return to citationEvans, P. & McCoy, A. (2008). Acta Cryst. D64, 1–10.  Web of Science CrossRef CAS IUCr Journals Google Scholar
Return to citationFling, S. P. & Gregerson, D. S. (1986). Anal. Biochem. 155, 83–88.  CrossRef CAS PubMed Google Scholar
Return to citationFricke, J. G., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., Geistlich, S., Schmid, D. E., Borgna, F., Fani, M., Bernhardt, P., van der Meulen, N. P., Müller, C., Schibli, R. & Wild, D. (2026). J. Nucl. Med. 67, 416–422.  CrossRef PubMed Google Scholar
Return to citationGasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R. D. & Bairoch, A. (2003). Nucleic Acids Res. 31, 3784–3788.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationGebauer, M. & Skerra, A. (2012). Methods Enzymol. 503, 157–188.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationGebauer, M. & Skerra, A. (2019). Curr. Opin. Biotechnol. 60, 230–241.  CrossRef CAS PubMed Google Scholar
Return to citationGiese, E. (2018). Clin. Med. Rep. 2, 1–2.  CrossRef Google Scholar
Return to citationGoetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N. & Strong, R. K. (2002). Mol. Cell, 10, 1033–1043.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationGoldenberg, D. M., Chang, C.-H., Rossi, E. A., McBride, W. J. & Sharkey, R. M. (2012). Theranostics, 2, 523–540.  CrossRef CAS PubMed Google Scholar
Return to citationGoldenberg, D. M. & Sharkey, R. M. (2006). Q. J. Nucl. Med. Mol. Imaging, 50, 248–264.  PubMed CAS Google Scholar
Return to citationHan, Y. R. & Lee, S. B. (2026). Oncol. Res. 34, 7.  PubMed Google Scholar
Return to citationHolliger, P. & Hudson, P. J. (2005). Nat. Biotechnol. 23, 1126–1136.  CrossRef PubMed CAS Google Scholar
Return to citationJoosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. (2014). IUCrJ, 1, 213–220.  Web of Science CrossRef CAS PubMed IUCr Journals Google Scholar
Return to citationKabsch, W. (2010). Acta Cryst. D66, 125–132.  Web of Science CrossRef CAS IUCr Journals Google Scholar
Return to citationKhosraviani, M., Blake, R. C., Pavlov, A. R., Lorbach, S. C., Yu, H., Delehanty, J. B., Brechbiel, M. W. & Blake, D. A. (2000). Bioconjug. Chem. 11, 267–277.  CrossRef PubMed CAS Google Scholar
Return to citationKim, H. J., Eichinger, A. & Skerra, A. (2009). J. Am. Chem. Soc. 131, 3565–3576.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationKrissinel, E. & Henrick, K. (2007). J. Mol. Biol. 372, 774–797.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationKubícek, V., Havlícková, J., Kotek, J., Tircsó, G., Hermann, P., Tóth, E. & Lukes, I. (2010). Inorg. Chem. 49, 10960–10969.  PubMed Google Scholar
Return to citationLanger, G., Cohen, S. X., Lamzin, V. S. & Perrakis, A. (2008). Nat. Protoc. 3, 1171–1179.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationLaskowski, R. A., Moss, D. S. & Thornton, J. M. (1993). J. Mol. Biol. 231, 1049–1067.  CrossRef CAS PubMed Web of Science Google Scholar
Return to citationLau, E. Y., Lightstone, F. C. & Colvin, M. E. (2006). Inorg. Chem. 45, 9225–9232.  CrossRef PubMed CAS Google Scholar
Return to citationLöfblom, J., Frejd, F. Y. & Ståhl, S. (2011). Curr. Opin. Biotechnol. 22, 843–848.  Web of Science PubMed Google Scholar
Return to citationLove, R. A., Villafranca, J. E., Aust, R. M., Nakamura, K. K., Jue, R. A., Major, J. G. Jr, Radhakrishnan, R. & Butler, W. F. (1993). Biochemistry, 32, 10950–10959.  CrossRef CAS PubMed Google Scholar
Return to citationLuo, Y., Zhang, J., Dong, Z. & Ding, Y. (2026). Int. J. Biol. Macromol. 357, 151623.  CrossRef PubMed Google Scholar
Return to citationMaecke, H. R., Riesen, A. & Ritter, W. (1989). J. Nucl. Med. 30, 1235–1239.  CAS PubMed Google Scholar
Return to citationMcMurry, T. J., Pippin, C. G., Wu, C., Deal, K. A., Brechbiel, M. W., Mirzadeh, S. & Gansow, O. A. (1998). J. Med. Chem. 41, 3546–3549.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationMeehan, P. R., Aris, D. R. & Willey, G. R. (1999). Coord. Chem. Rev. 181, 121–145.  CrossRef CAS Google Scholar
Return to citationMilenic, D. E., Brady, E. D. & Brechbiel, M. W. (2004). Nat. Rev. Drug Discov. 3, 488–499.  CrossRef PubMed CAS Google Scholar
Return to citationMorath, V., Brandt, C., Deuschle, F. C., Mendler, C. T., Blechert, B., Summer, D., Barinka, C., Decristoforo, C., Weber, W. A., Schwaiger, M. & Skerra, A. (2023). Mol. Pharm. 20, 2490–2501.  CrossRef CAS PubMed Google Scholar
Return to citationMorath, V., Fritschle, K., Warmuth, L., Anneser, M., Dötsch, S., Živanić, M., Krumwiede, L., Bösl, P., Bozoglu, T., Robu, S., Libertini, S., Kossatz, S., Kupatt, C., Schwaiger, M., Steiger, K., Busch, D. H., Skerra, A. & Weber, W. A. (2025). Nat. Biomed. Eng. 9, 1886–1906.  CrossRef CAS PubMed Google Scholar
Return to citationNawar, M. F., Selim, A. A., Essa, B. M., El-Daoushy, A. F., Swidan, M. M., Chambers, C. G., Al Qahtani, M. H., Smith, C. J. & Sakr, T. M. (2025). Cancers, 17, 3055.  CrossRef PubMed Google Scholar
Return to citationRichter, A., Eggenstein, E. & Skerra, A. (2014). FEBS Lett. 588, 213–218.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationRothe, C. & Skerra, A. (2018). BioDrugs, 32, 233–243.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationSadler, A. W. E., Hogan, L., Fraser, B. & Rendina, L. M. (2022). EJNMMI Radiopharm. Chem. 7, 21.  Google Scholar
Return to citationSchiefner, A. & Skerra, A. (2015). Acc. Chem. Res. 48, 976–985.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationSchmidt, T. G. & Skerra, A. (2007). Nat. Protoc. 2, 1528–1535.  CrossRef PubMed CAS Google Scholar
Return to citationShannon, R. D. (1976). Acta Cryst. A32, 751–767.  CrossRef CAS IUCr Journals Web of Science Google Scholar
Return to citationSkerra, A. (2000). Biochim. Biophys. Acta, 1482, 337–350.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationTrejtnar, F., Bárta, P., Kozempel, J., Vlk, M., Ďurinová, A., Kuchařová, M. & Pávek, P. (2025). Nucl. Med. Biol. 144–145, 108998.  CrossRef PubMed Google Scholar
Return to citationVan Laere, C., Koole, M., Deroose, C. M., de Voorde, M. V., Baete, K., Cocolios, T. E., Duchemin, C., Ooms, M. & Cleeren, F. (2024). Theranostics, 14, 1720–1743.  CrossRef CAS PubMed Google Scholar
Return to citationWachter, S., Angevin, T., Bubna, N., Tan, A., Cichy, A., Brown, D., Wolfe, L. S., Sappington, R., Lilla, E., Berry, L., Grismer, D., Orth, C., Blanusa, M., Mostafa, S., Kaufmann, H. & Felderer, K. (2023). J. Biotechnol. 377, 13–22.  CrossRef CAS PubMed Google Scholar
Return to citationWilliams, C. J., Headd, J. J., Moriarty, N. W., Prisant, M. G., Videau, L. L., Deis, L. N., Verma, V., Keedy, D. A., Hintze, B. J., Chen, V. B., Jain, S., Lewis, S. M., Arendall, W. B., Snoeyink, J., Adams, P. D., Lovell, S. C., Richardson, J. S. & Richardson, J. S. (2018). Protein Sci. 27, 293–315.  Web of Science CrossRef CAS PubMed Google Scholar

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.

Journal logoSTRUCTURAL BIOLOGY
COMMUNICATIONS
ISSN: 2053-230X